UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 31

Sortiert nach

Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox

The New England journal of medicine, 2019-11, Vol.381 (20), p.1897-1908

2019

Link zum Volltext

Verfügbarkeit prüfen

SUMO: a regulator of gene expression and genome integrity

Oncogene, 2004-03, Vol.23 (11), p.1998-2008

2004

Link zum Volltext

Verfügbarkeit prüfen

Members of the PIAS Family Act as SUMO Ligases for c-Jun and p53 and Repress p53 Activity

Proceedings of the National Academy of Sciences - PNAS, 2002-03, Vol.99 (5), p.2872-2877

2002

Link zum Volltext

Verfügbarkeit prüfen

Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial

PloS one, 2018-04, Vol.13 (4), p.e0195897-e0195897

2018

Link zum Volltext

Verfügbarkeit prüfen

Viral oncoproteins E1A and E7 and cellular LxCxE proteins repress SUMO modification of the retinoblastoma tumor suppressor

Oncogene, 2005-05, Vol.24 (23), p.3810-3818

2005

Link zum Volltext

Verfügbarkeit prüfen

Sumoylation of poly(ADP-ribose) polymerase 1 inhibits its acetylation and restrains transcriptional coactivator function

The FASEB journal, 2009-11, Vol.23 (11), p.3978-3989

2009

Link zum Volltext

Verfügbarkeit prüfen

Down-Regulation of c-Fos/c-Jun AP-1 Dimer Activity by Sumoylation

Molecular and Cellular Biology, 2005-08, Vol.25 (16), p.6964-6979

2005

Link zum Volltext

Verfügbarkeit prüfen

Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis

PloS one, 2015-11, Vol.10 (11), p.e0142802-e0142802

2015

Link zum Volltext

Verfügbarkeit prüfen

Safety and immunogenicity of a novel trivalent recombinant MVA-based equine encephalitis virus vaccine: A Phase 1 clinical trial

Vaccine, 2024-04, Vol.42 (10), p.2695-2706

2024

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase 3 trial to assess the immunogenicity and safety of 3 consecutively produced lots of freeze-dried MVA-BN® vaccine in healthy adults

Vaccine, 2023-01, Vol.41 (2), p.397-406

2023

Link zum Volltext

Verfügbarkeit prüfen

Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine

The Journal of infectious diseases, 2023-10, Vol.228 (8), p.999-1011

2023

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS

Vaccine, 2020-03, Vol.38 (11), p.2600-2607

2020

Link zum Volltext

Verfügbarkeit prüfen

Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine

The Journal of infectious diseases, 2021-03, Vol.223 (6), p.1062-1072

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trial

Vaccine, 2020-03, Vol.38 (11), p.2608-2619

2020

Link zum Volltext

Verfügbarkeit prüfen

One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines

The Journal of infectious diseases, 2023-05, Vol.227 (10), p.1203-1213

2023

Link zum Volltext

Verfügbarkeit prüfen

LB747. Immune Responses of the Recombinant MVA-BN-RSV Vaccine against Respiratory Syncytial Virus Infection in an RSV Human Challenge Trial (HCT) in Healthy Adult Participants

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Link zum Volltext

Verfügbarkeit prüfen

LB1579. A single and a two-dose regimen of MVA-BN elicit similar memory responses to a boost vaccination two years after the initial regimen, indicating potential flexibility for a delayed second dose of MVA-BN in the ongoing monkeypox emergency

Open forum infectious diseases, 2022-12, Vol.9 (Supplement_2)

2022

Link zum Volltext

Verfügbarkeit prüfen

Constitutive Crosspresentation of Tissue Antigens by Dendritic Cells Controls CD8+ T Cell Tolerance In Vivo

Immunity (Cambridge, Mass.), 2008-04, Vol.28 (4), p.521-532

2008

Link zum Volltext

Verfügbarkeit prüfen

LB11. A Single Dose of the MVA-BN Smallpox Vaccine Induces an Early Protective Antibody Response Similar to a Traditional Replicating Vaccine and Is Suitable for Emergency Scenarios

Open forum infectious diseases, 2019-10, Vol.6 (Supplement_2), p.S997-S998

2019

Link zum Volltext

Verfügbarkeit prüfen

Synergy of glucose and growth hormone signalling in islet cells through ICA512 and STAT5

Nature cell biology, 2006-05, Vol.8 (5), p.435-445

2006

Link zum Volltext

Verfügbarkeit prüfen

SUMO: a regulator of gene expression and genome integrity: Ubiquitination in cancer

Oncogene, 2004, Vol.23 (11), p.1998-2008

2004

Link zum Volltext

Verfügbarkeit prüfen

Article: Constitutive Crosspresentation of Tissue Antigens by Dendritic Cells Controls CD8 T Cell Tolerance In Vivo

Immunity (Cambridge, Mass.), 2008-04, Vol.28 (4), p.521-532

2008

Link zum Volltext

Verfügbarkeit prüfen

Bone scaffold architecture modulates the development of mineralized bone matrix by human embryonic stem cells

Biomaterials, 2012-11, Vol.33 (33), p.8329-8342

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(30)
Tagungsberichte
(1)

Sprache

Englisch
(31)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox

SUMO: a regulator of gene expression and genome integrity

Members of the PIAS Family Act as SUMO Ligases for c-Jun and p53 and Repress p53 Activity

Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial

Viral oncoproteins E1A and E7 and cellular LxCxE proteins repress SUMO modification of the retinoblastoma tumor suppressor

A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects

A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis

Sumoylation of poly(ADP-ribose) polymerase 1 inhibits its acetylation and restrains transcriptional coactivator function

Down-Regulation of c-Fos/c-Jun AP-1 Dimer Activity by Sumoylation

Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis

Safety and immunogenicity of a novel trivalent recombinant MVA-based equine encephalitis virus vaccine: A Phase 1 clinical trial

A randomized phase 3 trial to assess the immunogenicity and safety of 3 consecutively produced lots of freeze-dried MVA-BN® vaccine in healthy adults

Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: A Human Challenge Trial of MVA-BN-RSV Vaccine

A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS

Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine

Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trial

One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines

LB747. Immune Responses of the Recombinant MVA-BN-RSV Vaccine against Respiratory Syncytial Virus Infection in an RSV Human Challenge Trial (HCT) in Healthy Adult Participants

LB1579. A single and a two-dose regimen of MVA-BN elicit similar memory responses to a boost vaccination two years after the initial regimen, indicating potential flexibility for a delayed second dose of MVA-BN in the ongoing monkeypox emergency

Constitutive Crosspresentation of Tissue Antigens by Dendritic Cells Controls CD8+ T Cell Tolerance In Vivo

LB11. A Single Dose of the MVA-BN Smallpox Vaccine Induces an Early Protective Antibody Response Similar to a Traditional Replicating Vaccine and Is Suitable for Emergency Scenarios

Synergy of glucose and growth hormone signalling in islet cells through ICA512 and STAT5

SUMO: a regulator of gene expression and genome integrity: Ubiquitination in cancer

Article: Constitutive Crosspresentation of Tissue Antigens by Dendritic Cells Controls CD8 T Cell Tolerance In Vivo

Bone scaffold architecture modulates the development of mineralized bone matrix by human embryonic stem cells

Suchergebnisse filtern